There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Akero Therapeutics Inc. (AKRO) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.04, or -0.07%, to $54.76. The Akero Therapeutics Inc. has recorded 8,875 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $54.80 and fluctuated between $54.83 as its day high and $52.45 as its day low. The current market capitalization of Akero Therapeutics Inc. is $2.52B. A total of 0.76 million shares were traded on the day, compared to an average of 805.51K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, AKRO has seen 12 BUY and 42 SELL insider trades, representing the acquisition of 192,436 and the disposition of 2,108,083 shares. Over the last 12 months, there were 26 BUYs and 55 SELLs from insiders. Insiders purchased 429,988 shares during that period but sold 2,360,283.
In the most recent transaction, Rolph Timothy sold 20,316 shares of AKRO for 51.05 per share on Dec 29. After the transaction, the Chief Scientific Officer now owns 190,532 company shares. In a previous transaction on Dec 28, Rolph Timothy sold 1,700 shares at 50.00 per share. AKRO shares that Chief Scientific Officer owns now total 203,032.
Among the insiders who sold shares, White William Richard disposed of 999 shares on Dec 28 at a per-share price of $49.76. This resulted in the Chief Financial Officer holding 23,624 shares of AKRO after the transaction. In another insider transaction, White William Richard sold 19,001 shares at $49.77 per share on Dec 27. Company shares held by the Chief Financial Officer now total 23,624.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for AKRO in the last 3 months, the mean price target is $52.00 with high estimates of $64.00 and low estimates of $40.00. In terms of 52-week highs and lows, AKRO has a high of $53.98 and a low of $7.52.
As of this writing, AKRO has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.64 per share and a lower estimate of -$0.81. The company reported an EPS of -$0.74 in the last quarter, which was 7.50% higher than expectations of -$0.8.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Overweight with a score of 4.60. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.